SpliSense Ltd.
🇮🇱Israel
- Country
- 🇮🇱Israel
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://splisense.com
Clinical Trials
2
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients with Cystic Fibrosis
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- SpliSense Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT06429176
- Locations
- 🇺🇸
Boston Children'S Hospital, Boston, Massachusetts, United States
🇺🇸Nationwide Children'S Hospital, Columbus, Ohio, United States
Safety, Tolerability, and Pharmacokinetics of SPL84 in Healthy Volunteers
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- SpliSense Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT06217952
- Locations
- 🇮🇱
Hadassah Ein Kerem Hospital Clinical Research Center, Jerusalem, Israel
News
No news found